TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.

doi:10.1200/JCO.2010.32.7742

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Apr 2011

Metzeler Klaus H, Maharry Kati, Radmacher Michael D, Mrózek Krzysztof, Margeson Dean, Becker Heiko, Curfman John, Holland Kelsi B, Schwind Sebastian, Whitman Susan P, Wu Yue-Zhong, Blum William, Powell Bayard L, Carter Thomas H, Wetzler Meir, Moore Joseph O, Kolitz Jonathan E, Baer Maria R, Carroll Andrew J, Larson Richard A, Caligiuri Michael A, Marcucci Guido, Bloomfield Clara D

Abstract excerpt

PURPOSE: To determine the frequency of TET2 mutations, their associations with clinical and molecular characteristics and outcome, and the associated gene- and microRNA-expression signatures in patients with primary cytogenetically normal acute myeloid leukemia (CN-AML). PATIENTS AND METHODS: Four-hundred twenty-seven patients with CN-AML were analyzed for TET2 mutations by polymerase chain reaction and direct...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytogenetic Analysis

Share to Dioxygenases

Share to Disease-Free Survival

Share to Gene Expression Regulation, Leukemic

Share to Kaplan-Meier Estimate

Share to Nucleophosmin

Share to Proportional Hazards Models

Source

Open in PubMed Open full text

Identifiers

PMID: 21343549
DOI: 10.1200/JCO.2010.32.7742
PMCID: PMC3084003

Genes

TET2
ELN
FLT3
EFS
NPM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.PMID 21343549Read ↗

TET2 gene mutation is unfavorable prognostic factor in cytogenetically normal acute myeloid leukemia patients with NPM1+ and FLT3-ITD - mutations.Semantic proximity Read ↗

TET2 mutations in cytogenetically normal acute myeloid leukemia: clinical implications and evolutionary patterns.Semantic proximity Read ↗

TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics.Semantic proximity Read ↗

High Expression of TET1 Predicts Poor Survival in Cytogenetically Normal Acute Myeloid Leukemia From Two CohortsSemantic proximity Read ↗

The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysisSemantic proximity Read ↗

TET2 mutations contribute to adverse prognosis in acute myeloid leukemia (AML): results from a comprehensive analysis of 502 AML cases and the Beat AML public databaseSemantic proximity Read ↗

TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemiaSemantic proximity Read ↗

Clinical Implication of DNMT3A and TET2 Genes Mutations in Cytogenetically Normal Acute Myeloid Leukemia.Semantic proximity Read ↗

Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features.Semantic proximity Read ↗

A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice.Semantic proximity Read ↗

Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years.Semantic proximity Read ↗

Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.